The global oncolytic adenovirus market is expected to garner a market value of US$ 121.30 Billion in 2023 and is expected to accumulate a market value of US$ 250 Billion by registering a CAGR of 7.5% in the forecast period 2023 to 2033. Growth of the oncolytic adenovirus market can be attributed to the Increasing prevalence of oncology globally coupled with a surge in Research and Development efforts to develop novel oncology therapeutics. These are the major driving factors for the market. The market for oncolytic adenovirus registered a CAGR of 4.9% in the historical period 2018 to 2022
Moreover, the presence of various organizations that support immunotherapy research is also expected to fuel market growth. For instance, Parker Institute for Cancer Immunotherapy collaborated with researchers and industry leaders to develop breakthrough immune therapies for cancer.
According to the Global Cancer Observatory, the US reported around 2,281,658 cancer cases in 2020 and 612,390 cancer-related deaths. The most common malignancies affecting the US population are breast, prostate, lung, and colorectal. In addition, according to the Cancer Council, Australia reported 150,000 new cancer cases with 50,000 deaths in 2020. Thus, the surge in the prevalence of malignant tumor cases is anticipated to accelerate market expansion in the coming years.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 121.30 Billion |
| Anticipated Forecast Value (2033) | US$ 250 Billion |
| Projected Growth Rate (2023 to 2033) | 7.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for oncolytic adenovirus reflected a value of 4.9% during the historical period, 2017 to 2022.
The increasing prevalence of different types of cancers is a significant factor driving the market's growth. In addition, the presence of various immunotherapies to treat cancer at different stages in creating a positive demand for oncolytic adenovirus. Furthermore, the COVID-19 pandemic affected the research and development activities related to oncolytic adenovirus due to the disruption in the supply chain demand globally.
Thus, the market for Oncolytic adenovirus is expected to register a CAGR of 7.5% in the forecast period 2023 to 2033.
Improving patient outcomes by advancing the science and application of oncolytic adenovirus
The presence of various government and non-government organizations that create awareness and promote research is augmenting market expansion. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 Billion in research. Moreover, the Society for Immunotherapy of Cancer(SITC) is engaged in improving patient outcomes by advancing the science and application of oncolytic adenovirus. These organizations are working with scientists and researchers to discover novel treatment regimens of immune therapy.
Furthermore, increasing funding for the development of novel treatments is expected to boost Research and Development activities to develop cancer immunotherapy. For instance, in June 2022, Stanford scientists received USD 13 Billion from Cancer Grand Challenges, a funding initiative by Cancer Research UK and the US National Cancer Institute. This funding is awarded for the development of next-generation immunotherapies, the study of extrachromosomal DNA, and the investigation of early-stage malignancies.
Increasing approval of novel immunotherapies is anticipated to propel the market growth over the forecast period. From 2020 to 2022, the U.S. FDA has approved various anti-PD-1/L1 antibodies such as nivolumab, atezolizumab, avelumab, dostarlimab, and others for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate malignancies, and others. The higher approvals of immunotherapeutic agents have propelled the market growth.
Strategic initiatives by leading players propelling the market growth
Various Strategic initiatives undertaken by leading players are also expected to facilitate the market demand. For instance, in August 2022, BioNTech SE and Genmab A/S expanded their strategic collaboration for the development and launch of new immune therapies for the treatment of various cancer forms. Moreover, in March 2022, Merck & Co., Inc announced the approval of KEYTRUDA from the US FDA. KEYTRUDA is an anti-PD-1 therapy for treating advanced endometrial carcinoma.
However, side effects associated with immunotherapy will likely hamper the cancer treatment prescription rate. The available therapies are associated with several adverse effects, such as pain, insomnia, fatigue, nausea, and gastrointestinal conditions. These adverse effects impact the overall quality of life of patients and the management of these adverse effects incurs extra costs. In addition, prolonged consumption of immunotherapeutic drugs may cause severe damage to the organs and increase the incidence of organ failure cases.
Principal Consultant
Antiviral immune response creating challenges for the oncolytic adenovirus market
Although oncolytic adenovirus has remarkable antitumor potency, it is confronted with tough challenges such as antiviral immune response and obstruction of the tumor microenvironment (TME). This has led to a significant debate on the efficiency and application of oncolytic adenovirus for cancer treatment.
Furthermore, the time taken for approval of therapies and medications for cancer is derailing the progress of the market. In addition, the efficiency of drugs and their long-lasting impact is still being tested. All these factors are hampering the growth of the oncolytic adenovirus market.
Government and non-government organizations supporting research activities for oncolytic adenovirus in North America
In 2022, North America led the overall market in terms of revenue due to the presence of a large number of leading players coupled with various Strategic initiatives undertaken by them. Moreover, the increase in disease prevalence, various government and non-government organizations promoting research activities for cancer immunotherapy, and the increasing approval of novel drugs are fueling the regional market growth. For instance, in April 2022, the US FDA approved Opdivo (nivolumab) for treating NSCLC in adult patients.
Thus, North America is expected to possess a 43% market share for the oncolytic adenovirus market in 2023.
Investments in research and healthcare infrastructure create lucrative opportunities for the oncolytic adenovirus market
Asia Pacific is projected to witness the fastest growth rate over the forecast period. The increase in the geriatric population, a large patient base of targeted diseases, and improving healthcare infrastructure are some of the primary factors driving the growth.
Moreover, the rising regulatory approvals of immune therapies in the region are also contributing region’s expansion. For instance, from 2020 to 2022, the National Medical Products Administration of China approved Pembrolizumab and Durvalumab to treat esophageal cancer and SCLC.
Thus, Asia Pacific is expected to possess a 39% market share for the oncolytic adenovirus market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Product approval for treating lung cancer boosting segment growth
The rising prevalence of lung malignancies, increasing adoption of immunotherapy, rise in awareness programs, and presence of a robust pipeline of investigational candidates are some of the key factors expected to drive the segment's growth. Furthermore, rising product approval and product launches fueling the demand forward. For instance, in October 2021, the US FDA approved Tecentriq (atezolizumab) to treat stage II and stage III NSCLC.
Thus, lung cancer is expected to possess a 35% market share for oncolytic adenovirus in 2023.
Key players in the oncolytic adenovirus market are Amgen, Sorrento Therapeutics, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, CG Oncology Inc, VCNBiosciences, DNAtrix, Replimune Group Inc
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 121.30 Billion |
| Market Value in 2033 | US$ 250 Billion |
| Growth Rate | CAGR of 7.5% from 2023 to 2033 |
| Base Year for Estimation | 2021 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
From 2017 to 2022, the oncolytic adenovirus market grew at a CAGR of 4.9%
The global oncolytic adenovirus market is expected to grow with a 7.5% CAGR from 2023 to 2033.
As of 2033, the oncolytic adenovirus market is expected to reach US$ 250 Billion
Lung cancer is expected to possess a 35% market share for oncolytic adenovirus in 2023.
North America is expected to possess a 43% market share for the oncolytic adenovirus market in 2023.
Asia Pacific's oncolytic adenovirus market size is expected to possess a 39% market share in 2023.
1. Executive Summary | Oncolytic Adenovirus Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Types
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Types, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Types, 2023 to 2033
5.3.1. HSV-based Oncolytic Viruses
5.3.2. Adenoviruses-based Oncolytic Viruses
5.3.3. Others
5.4. Y-o-Y Growth Trend Analysis By Types, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Types, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Applications
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Applications, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Applications, 2023 to 2033
6.3.1. Melanoma
6.3.2. Prostate Cancer
6.3.3. Breast Cancer
6.3.4. Ovarian Cancer
6.3.5. Lung Cancer
6.3.6. Others
6.4. Y-o-Y Growth Trend Analysis By Applications, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Applications, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The US
8.2.1.2. Canada
8.2.2. By Types
8.2.3. By Applications
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Types
8.3.3. By Applications
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Types
9.2.3. By Applications
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Types
9.3.3. By Applications
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. The UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Types
10.2.3. By Applications
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Types
10.3.3. By Applications
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Types
11.2.3. By Applications
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Types
11.3.3. By Applications
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Types
12.2.3. By Applications
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Types
12.3.3. By Applications
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Types
13.2.3. By Applications
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Types
13.3.3. By Applications
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Types
14.2.3. By Applications
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Types
14.3.3. By Applications
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. The US
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Types
15.1.2.2. By Applications
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Types
15.2.2.2. By Applications
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Types
15.3.2.2. By Applications
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Types
15.4.2.2. By Applications
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Types
15.5.2.2. By Applications
15.6. The UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Types
15.6.2.2. By Applications
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Types
15.7.2.2. By Applications
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Types
15.8.2.2. By Applications
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Types
15.9.2.2. By Applications
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Types
15.10.2.2. By Applications
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Types
15.11.2.2. By Applications
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Types
15.12.2.2. By Applications
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Types
15.13.2.2. By Applications
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Types
15.14.2.2. By Applications
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Types
15.15.2.2. By Applications
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Types
15.16.2.2. By Applications
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Types
15.17.2.2. By Applications
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Types
15.18.2.2. By Applications
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Types
15.19.2.2. By Applications
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Types
15.20.2.2. By Applications
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Types
15.21.2.2. By Applications
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Types
16.3.3. By Applications
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Amgen
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Sorrento Therapeutics
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Transgene SA
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Oncolys BioPharma
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Targovax
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Lokon Pharma
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Vyriad
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. TILT Biotherapeutics
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. CG Oncology Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. VCNBiosciences
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. DNAtrix
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Replimune Group Inc.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Oncolytic Adenovirus Market
